Literature DB >> 11462196

Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis.

C S Graham1, L R Baden, E Yu, J M Mrus, J Carnie, T Heeren, M J Koziel.   

Abstract

Studies have shown that rates of liver disease are higher in persons who are coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) than they are in persons with HCV alone, but estimates of risk vary widely and are based on data for dissimilar patient populations. We performed a meta-analysis to quantify the effect of HIV coinfection on progressive liver disease in persons with HCV. Eight studies were identified that included outcomes of histological cirrhosis or decompensated liver disease. These studies yielded a combined adjusted relative risk (RR) of 2.92 (95% confidence interval [CI], 1.70-5.01). Of note, studies that examined decompensated liver disease had a combined RR of 6.14 (95% CI, 2.86-13.20), whereas studies that examined histological cirrhosis had a pooled RR of 2.07 (95% CI, 1.40-3.07). There is a significantly elevated RR of severe liver disease in persons who are coinfected with HIV and HCV. This has important implications for timely diagnosis and consideration of treatment in coinfected persons.

Entities:  

Mesh:

Year:  2001        PMID: 11462196     DOI: 10.1086/321909

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  272 in total

Review 1.  When to treat patients with chronic hepatitis C.

Authors:  Jenny Heathcote; Alnoor Ramji
Journal:  Curr Gastroenterol Rep       Date:  2004-08

Review 2.  Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015.

Authors:  Pankaj Puri; Anil C Anand; Vivek A Saraswat; Subrat K Acharya; Radha K Dhiman; Shiv K Sarin; Shivaram P Singh; Yogesh K Chawla; Rakesh Aggarwal; Deepak Amarapurkar; Anil Arora; Vinod K Dixit; Ajit Sood; Samir Shah; Ajay Duseja; Dharmesh Kapoor; Kaushal Madan; Gaurav Pande; Aabha Nagral; Premashis Kar; Abraham Koshy; Amarender S Puri; C E Eapen; Sandeep Thareja
Journal:  J Clin Exp Hepatol       Date:  2015-09-21

3.  Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes.

Authors:  J Macías; J A Girón-González; M González-Serrano; D Merino; P Cano; J A Mira; A Arizcorreta-Yarza; J Ruíz-Morales; J M Lomas-Cabeza; J A García-García; J E Corzo; J A Pineda
Journal:  Gut       Date:  2005-08-23       Impact factor: 23.059

Review 4.  The other genome: a systematic review of studies of mitochondrial DNA haplogroups and outcomes of HIV infection and antiretroviral therapy.

Authors:  Anna B Hart; David C Samuels; Todd Hulgan
Journal:  AIDS Rev       Date:  2013 Oct-Dec       Impact factor: 2.500

5.  Hepatitis C and HIV-1 coinfection.

Authors:  A H Mohsen; P Easterbrook; C B Taylor; S Norris
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

6.  Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and hepatitis C virus-coinfected veterans.

Authors:  Jeffrey P Anderson; Eric J Tchetgen Tchetgen; Vincent Lo Re; Janet P Tate; Paige L Williams; George R Seage; C Robert Horsburgh; Joseph K Lim; Matthew Bidwell Goetz; David Rimland; Maria C Rodriguez-Barradas; Adeel A Butt; Marina B Klein; Amy C Justice
Journal:  Clin Infect Dis       Date:  2013-11-27       Impact factor: 9.079

7.  Effectiveness and security of chronic hepatitis C treatment in coinfected patients in real-world.

Authors:  Moisés Uriarte-Pinto; Herminia Navarro-Aznarez; Natalia De La Llama-Celis; Piedad Arazo-Garcés; Ana María Martínez-Sapiña; María Reyes Abad-Sazatornil
Journal:  Int J Clin Pharm       Date:  2018-03-20

8.  Statin drugs decrease progression to cirrhosis in HIV/hepatitis C virus coinfected individuals.

Authors:  Nora T Oliver; Christine M Hartman; Jennifer R Kramer; Elizabeth Y Chiao
Journal:  AIDS       Date:  2016-10-23       Impact factor: 4.177

9.  HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing.

Authors:  T Ruggiero; E Burdino; A Calcagno; S Bonora; L Boglione; G Di Perri; V Ghisetti
Journal:  Infection       Date:  2016-08-13       Impact factor: 3.553

10.  Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution.

Authors:  Ashwin Balagopal; Stuart C Ray; Ruben Montes De Oca; Catherine G Sutcliffe; Perumal Vivekanandan; Yvonne Higgins; Shruti H Mehta; Richard D Moore; Mark S Sulkowski; David L Thomas; Michael S Torbenson
Journal:  AIDS       Date:  2009-11-27       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.